HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NO-mesalamine

structure in first source

Also Known As:

NCX-456; NCX456

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Farneti, Silvana: 1 article (05/2005)
2.	Fiorucci, Stefano: 1 article (05/2005)
3.	Mencarelli, Andrea: 1 article (05/2005)
4.	Morelli, Antonio: 1 article (05/2005)
5.	Santucci, Luca: 1 article (05/2005)
6.	Wallace, John: 1 article (05/2005)

Related Diseases

1.	Colitis 09/01/1999 - "NO-mesalamine was significantly more effective than mesalamine in reducing the severity of colitis (damage and granulocyte infiltration). " 05/01/2005 - "NCX-456, but not mesalamine, administration resulted in a marked reduction in clinical, histological, and immunologic signs of colitis in both models. " 09/01/1999 - "Effects of an NO-releasing derivative of mesalamine (NCX-456; NO-mesalamine) were compared with those of mesalamine itself and 2 other NO donors in a rat model of colitis. " 05/01/2005 - "Cells and tissues from mice with 2,4,6-trinitrobenzene sulfonic acid-induced colitis and from interleukin 10-deficient mice with spontaneous chronic colitis receiving treatment with several doses of NCX-456 or mesalamine were analyzed for morphology, cytokine production, and apoptosis. "
2.	Inflammation (Inflammations) 05/01/2005 - "Collectively, these data show that NCX-456 inhibits lamina propria T-helper type 1 function and stimulates the activity of interleukin 10- and transforming growth factor beta-secreting cells, thus restoring mucosal immune homeostasis and suppressing intestinal inflammation."

Related Drugs and Biologics

1.	Mesalamine (Mesalazine)
2.	Interleukin-10 (Interleukin 10)
3.	Transforming Growth Factor beta (TGF-beta)
4.	Cytokines
5.	Sulfonic Acids
6.	Interleukins
7.	sym-trinitrobenzene